Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Annovis Bio Inc
(NY:
ANVS
)
5.390
+0.210 (+4.05%)
Official Closing Price
Updated: 7:00 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Annovis Bio Inc
< Previous
1
2
3
4
5
Next >
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
April 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
FDA Guides Annovis Bio For Two Phase 3 Buntanetap Trial In Parkinson's Disease
January 25, 2022
Annovis Bio Inc (NYSE: ANVS) has completed a Type B meeting with the FDA regarding its planned Phase 3 studies of Buntanetap for the treatment of Parkinson's...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
December 27, 2021
Gainers OptiNose (NASDAQ:OPTN) shares mov...
Via
Benzinga
Annovis Bio on Its Positive Results in Alzheimer's and Parkinson's Clinical Trials
December 27, 2021
Image provided by Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
December 03, 2021
Gainers Lixte Biotech Holdings (NASDAQ:LIXT
Via
Benzinga
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
November 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...
Via
Benzinga
Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market
October 21, 2021
Cortexyme is testing a twice-day pill to treat Alzheimer's disease.
Via
Investor's Business Daily
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...
Via
Benzinga
44 Biggest Movers From Yesterday
October 15, 2021
Gainers Benessere Capital Acquisition Corp. (NASDAQ: BENER) shares jumped 66.5% to close at $0.4530 on Thursday. Grove, Inc. (NASDAQ: GRVI) gained 39.3% to close at $6.98 after...
Via
Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
3 Stocks Insiders Are Buying
October 14, 2021
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go...
Via
Benzinga
92 Biggest Movers From Friday
November 08, 2021
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the...
Via
Benzinga
EXCLUSIVE: Annovis Bio's Parkinson's Candidate Improves Speed, Motor Function Vs Placebo
October 05, 2021
Annovis Bio Inc (NYSE: ANVS) has announced efficacy data from the Phase 2 trial evaluating ANVS401 in Parkinson's disease (PD). Data from 54 patients found that once-...
Via
Benzinga
The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
August 26, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
COVID-19
Better Biotech Stock: Cassava Sciences vs. Annovis Bio
August 26, 2021
It boils down to which company's clinical trial results look better for treating Alzheimer's at the moment.
Via
The Motley Fool
Why Is Biogen Pursuing a New Direction in Alzheimer's Research?
August 13, 2021
It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease.
Via
The Motley Fool
61 Biggest Movers From Yesterday
August 03, 2021
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program....
Via
Benzinga
99 Biggest Movers From Yesterday
August 06, 2021
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...
Via
Benzinga
40 Stocks Moving In Monday's Mid-Day Session
August 02, 2021
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million stock repurchase program. Exicure, Inc. (NASDAQ:...
Via
Benzinga
Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
July 29, 2021
A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.
Via
The Motley Fool
ANVS Stock: The Alzheimer’s Drug News That Has Annovis Bio Plunging Today
July 29, 2021
Shares of ANVS stock are plummeting on Thursday after Annovis Bio reported weak results from two clinical trials for its leading drug.
Via
InvestorPlace
63 Biggest Movers From Friday
August 02, 2021
Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares surged 55% to close at $6.37 on Friday after the company said the FDA has granted its eryaspase fast track designation for the...
Via
Benzinga
Exposures
Product Safety
Annovis Bio Shares Cut In Half Following Alzheimer's Data Presentation
July 29, 2021
Annovis Bio, Inc. (NYSE: ANVS), which took off on a strong rally in January, has quickly lost most of the gains. What To Know: Annovis, a clinical-stage neurodegenerative diseases...
Via
Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
August 01, 2021
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....
Via
Benzinga
Exposures
Product Safety
70 Biggest Movers From Yesterday
July 30, 2021
Gainers Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares surged 65.1% to settle at $5.30 on Thursday. Xenetic Biosciences recently reported closing of $12.5 million private...
Via
Benzinga
Mid-Day Market Update: LendingClub Surges Following Strong Q2 Results; Atreca Shares Plummet
July 29, 2021
Midway through trading Thursday, the Dow traded up 0.55% to 35,122.75 while the NASDAQ rose 0.47% to 14,831.28. The S&P also rose, gaining 0.61% to 4,427.36. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
44 Stocks Moving In Thursday's Mid-Day Session
July 29, 2021
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 47.6% to $2.8198 after the company announced it received registration approval for UroShield from TGA Australia....
Via
Benzinga
Mid-Morning Market Update: Markets Open Higher; Mastercard Profit Beats Estimates
July 29, 2021
Following the market opening Thursday, the Dow traded up 0.44% to 35,085.92 while the NASDAQ rose 0.27% to 14,802.51. The S&P also rose, gaining 0.45% to 4,420.49. The U.S....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Annovis Bio Stock Crashes After Much-Hyped Alzheimer's Drug Flops In Midstage Test
July 29, 2021
Annovis Bio's Alzheimer's drug failed to significantly outperform the placebo in a midstage test, leading ANVS stock to plummet on Thursday.
Via
Investor's Business Daily
28 Stocks Moving in Thursday's Pre-Market Session
July 29, 2021
Gainers LendingClub Corporation (NYSE: LC) shares rose 44.6% to $23.49 in pre-market trading after the company reported better-than-expected Q2 results and raised guidance. Acer...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.